Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets. [electronic resource]
Producer: 20201105Description: 143-153 p. digitalISSN:- 2376-1032
- Adult
- Blood Glucose -- drug effects
- Cost-Benefit Analysis
- Diabetes Mellitus, Type 2 -- drug therapy
- Drug Combinations
- Glycated Hemoglobin -- metabolism
- Humans
- Hypoglycemia -- chemically induced
- Hypoglycemic Agents -- administration & dosage
- Insulin Glargine -- administration & dosage
- Insulin, Long-Acting -- administration & dosage
- Liraglutide -- administration & dosage
- Metformin -- administration & dosage
- United States
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.